True Wealth Design’s Teva Pharmaceuticals TEVA Stock Holding History

True Wealth Design’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.6K	Buy	431 +37	+9%	+$1.23K	﹤0.01%	937
2026 Q1	$11.9K	Hold	394	–	–	﹤0.01%	921
2025 Q4	$12.3K	Buy	394 +28	+8%	+$690	﹤0.01%	785
2025 Q3	$7.39K	Buy	366 +66	+22%	+$1.16K	﹤0.01%	944
2025 Q2	$5.03K	Hold	300	–	–	﹤0.01%	802
2025 Q1	$4.61K	Hold	300	–	–	﹤0.01%	714
2024 Q4	$6.61K	Hold	300	–	–	﹤0.01%	481
2024 Q3	$5.41K	Hold	300	–	–	﹤0.01%	537
2024 Q2	$4.88K	Hold	300	–	–	﹤0.01%	285
2024 Q1	$4.23K	Hold	300	–	–	﹤0.01%	287
2023 Q4	$3.13K	Hold	300	–	–	﹤0.01%	284
2023 Q3	$3.06K	Hold	300	–	–	﹤0.01%	245
2023 Q2	$2.26K	Hold	300	–	–	﹤0.01%	269
2023 Q1	$2.65K	Hold	300	–	–	﹤0.01%	316
2022 Q4	$2.74K	Buy	+300	New	+$2.62K	﹤0.01%	280

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

True Wealth Design's TEVA Position: Q2 2026 in Review

True Wealth Design increased its Teva Pharmaceuticals (TEVA) stake by 9.4% in Q2 2026, buying an estimated $1.23K and bringing the position to 431 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #937.

True Wealth Design first reported a position in TEVA in Q4 2022 and has held it in 15 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

True Wealth Design held 431 shares of Teva Pharmaceuticals worth $14.6K as of Q2 2026.
True Wealth Design bought 37 Teva Pharmaceuticals shares in Q2 2026, an estimated $1.23K.
Teva Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #937 holding.
True Wealth Design first reported a position in Teva Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.